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ABSTRACT
The design and synthesis of a phthalocyanine – Gd-DOTA
conjugate is presented to open the way to novel molecular
theranostics, combining the properties of MRI contrast imag-
ing with photodynamic therapy. The rational design of the
conjugate integrates isomeric purity of the phthalocyanine
core substitution, suitable biocompatibility with the use of
polyoxo water-solubilizing substituents, and a convergent
synthetic strategy ended by the use of click chemistry to graft
the Gd-DOTA moiety to the phthalocyanine. Photophysical
and photochemical properties, contrast imaging experiments
and preliminary in vitro investigations proved that such a
combination is relevant and lead to a new type of potential
theranostic agent.
INTRODUCTION
Theranostics is one of the promising ways to personalized medi-
cine, more especially against cancer, combining diagnostic and
therapeutic effects (1,2). Most of theranostics are nanoobjects as
they allow easily combining the different features required (3),
when molecular theranostics are rather rare due to the difﬁculty
of combining several properties and effects in a unique chemical
derivative. Since the premises of modern photodynamic therapy,
the drawbacks of the ﬁrst-generation of photosensitizers, mainly
due to their polymeric poorly characterizable structures have
been overcome by the development of second-generation of
photosensitizers, consisting mainly of molecular tetrapyrroles of
well-deﬁned structures and tailorable properties (4). The third
generation of photosensitizers combines imaging agents and
photosensitizers to have the patient beneﬁting from a “see and
treat” process (5), and theranostics quickly took place in the pho-
todynamic therapy ﬁeld. Among the different types of photosen-
sitizers, porphyrins (6) and phthalocyanines (7,8) are particularly
employed. Zn(II) phthalocyanines offer the advantage of its near-
infra red absorption, centered at 700 nm and adjustable by play-
ing on the substitution pattern (9,10). Near-infrared red absorp-
tion has the double advantage of a deeper penetration of the
light into tissues, and to ﬁt the biological therapeutic window a
biological components does not absorb at these wavelengths.
Besides, phthalocyanines are extremely stable, compared for
example to chlorins absorbing at similar wavelengths but less
photostable (11). A wide range of nanoparticles has been
reported (12–15), when only a few examples of molecular thera-
nostic for PDT are described (16,17). In most cases, imaging
properties are ﬂuorescence-based, phthalocyanines being intrinsi-
cally good ﬂuorescent probes (18). Nevertheless, labeling of por-
phyrins and phthalocyanines by radioelements (19), such as 18F-
radiolabeling for PET imaging is reported (20).
Nowadays, computer tomography is the most common imag-
ing technique, PET being the most common for tumors. Contrast
magnetic resonance imaging (MRI) is an imaging modality
accessible in radiological practice, particularly for the identiﬁca-
tion and characterization of delicate tissue pathologies, especially
solid tumors in cancer, as a non-invasive diagnostic imaging
technique utilized within clinical and biomedical examination.
The affectability and speciﬁcity, and consequently differentiation
of MR images, might be further upgraded by the utilization of
responsive contrast agents. The majority of MRI contrast agents
are paramagnetic complexes made of cyclen-based chelates of
lanthanide ions, generally gadolinium (Gd3+)-based chelates (21–
23). A wide sort of paramagnetic chelates based on Gd(III), have
been contrived as T1 contrast agents (positive contrast agents) to
create a large magnetic moment. Such complexes are known to
exhibit nephrotoxic effects (24). This prompts researchers to
direct their efforts toward new imaging techniques. These effects
are still balanced by their powerful imaging properties. At pres-
ent, Gd-based contrast agents have been employed in >40% of
MRI scans, acting an important role in contrast enhanced MRI
studies (25–28). Diethylene triamine pentaacetic acid Gd com-
plexes are the most widely used ones, as is the commercially*Corresponding author email: gurek@gyte.edu.tr (Ayse G€ul G€urek)
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available Magnevist, Omniscan being a bismethylamide
substituted diethylene triamine pentaacetic acid Gd complex (29).
The efﬁcacy of these contrast agents depends on the interchang-
ing of water between the bulk solvent and the coordination
sphere. The swapping scale of bound water relies upon nature of
the ligand and the metal ion. Complexes made with the chelator
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)
exhibit the fastest rate of bound water.
For the last several years, our laboratory has focused its
research on developing NIR absorbing photosensitizers with a
phthalocyanine core (30–34), with enhanced efﬁcacy thanks to
various strategies: targeting (35), dual antivascular action
(36,37), nanoparticles functionalization (38,39). We then wished
to explore the possibility to produce PDT sensitizers having MRI
contrast imaging properties, to enlarge the range of available
techniques for dual imaging and photosensitization, and obtain a
novel type of theranostic agent. We selected a DOTA unit com-
plexing a gadolinium atom as the MRI contrast agent, coupled to
a Zn phthalocyanine core with known photosensitizing proper-
ties. To our knowledge, such strategy has not been developed
yet: the only DOTA-phthalocyanine conjugate reported so far
includes 68 Ga to be used as PET/ﬂuorescent dual imaging probe
(40).
In this paper, we report the design and the synthesis as well
as the theranostic dual photodynamic and imaging potential of
the phthalocyanine-GdDOTA conjugate 8.
MATERIALS AND METHODS
General methods. 1H and 13C nuclear magnetic resonance (NMR) spectra
were recorded by Varian 500 MHz spectrometer at 500 and 125 MHz,
respectively. Unless otherwise stated, chemical shifts are reported in ppm
and referenced to residual solvent resonance peaks (CDCl3: 7.26 ppm for
1H and 77.2 ppm for 13C, DMF-d7: 8.03, 2.92, 2.75 ppm for
1H and
163.15, 34.89, 29.76 ppm for 13C, DMSO-d6: 2.50 ppm for
1H and
39.51 ppm for 13C). Normal resolution mass spectra were recorded on a
LCQ-ion trap (Thermo Finnigan, San Jose, CA), equipped with an ES
(Electrospray) ionization source. High-resolution MALDI spectra for 6
and 8 were obtained as follows: the matrix solution was 20 mg mL1
2,5-dihydroxy benzoic acid (DHB) in 30% acetonitrile/70% aqueous
0.1% triﬂuoroacetic acid (v/v) for measuring conjugate 8. Sample was
dissolved in Milli-Q water and one lL was mixed with 1 lL of matrix.
One lL of the resulting mixture was spotted on the MTP 384 polished
steel plate. Sample was allowed to air dry and crystallizes before the tar-
get was loaded into the mass spectrometer. Mass spectra were obtained
in positive reﬂectron ion mode using Autoﬂex Speed MALDI-TOF mass
spectrometer (Bruker Daltonics, Bremen, Germany) with an acceleration
voltage of 19 kV and laser frequency of 1 Hz. The laser power was set
at 40% to 100% of the maximum. Signals from 500 shots were accumu-
lated for each spectrum. For external calibration the standard peptide
mixture “Peptide Mix II” (Bruker Daltonics) was used. ICP-MS was per-
formed on Thermo X series II. Each sample was acquired using 1 survey
run (10 sweeps) and 3 main (peak jumping) runs (100 sweeps). The iso-
topes selected were 156,157Gd for acquisition, with 115In, 165Ho and 209Bi
as internal standards for data interpolation and machine stability. Conju-
gate 8 (1 mg) was dissolved in concentrated nitric acid (1 mL) and soni-
cated for 15 min. After appropriate dilution in 5% aq. HNO3 solution (v/
v %) samples were fed to ICP-mass spectrometer. Ratio of Zn to Gd
metal ions was calculated based on obtained concentration values. IR
spectra were recorded on a Perkin Elmer 100 FTIR spectrometer. All sol-
vents and chemicals were of reagent-grade quality, purchased from
Sigma-Aldrich Chemical Co. and Merck, and used as received. 1,3-diph-
enylisobenzofuran (DPBF) was purchased from Fluka. Unless otherwise
indicated, organic extracts were dried over anhydrous sodium sulfate and
concentrated under reduced pressure using a rotary evaporator. Puriﬁca-
tion by column chromatography was performed using Merck Kieselgel
60 silica gel as the stationary phase. Ultra-pure water was obtained from
a Milli-Q Water System (Sartorius arium 611 UV). 4,5-bis(4,7,
10-trioxaundecane1-sulfonyl)phthalonitrile (41), 4-(carboxyethylsulpha-
nyl) phthalonitrile 2 (42), 3-azido-aminopropylamine (43) and Gd(III)
derivatives (Gd-595 MW 595 g mol1) (44,45) were synthesized accord-
ing to previously described procedures.
Syntheses. SynthesisofN-(3-azidopropyl)-3-((3,4-dicyanophenyl)thio)
propanamide (4). 4-Carboxyethylsulfanyl phthalonitrile 2 (300 mg,
1.3 mmol) was dissolved in anhydrous THF (5 mL) under argon atmo-
sphere, then thionyl chloride (1.6 g, 13.3 mmol) in anhydrous toluene
(5 mL) was added and the solution was reﬂuxed for 3 h. Thereafter,
solvents and excess of thionyl chloride were evaporated under reduce
pressure. Brown oil was dissolved in anhydrous THF (5 mL) and 1-
azido-3-aminopropane 3 (390 mg, 3.9 mmol) (as a free base) in anhy-
drous THF (5 mL) was added slowly drop by drop, then the mixture
was reﬂuxed for 3 h. The crude product was concentrated under reduce
pressure, suspended in water and extracted three times with ethyl ace-
tate. Organic layer was then extracted with brine, dried over anhydrous
Na2SO4 and puriﬁed by column chromatography on silica with dichlo-
romethane/ethyl acetate 100:1 as eluent followed by recrystallization
from ethanol yielding yellowish solid (280 mg, 68%). FT-IR (cm1)
3229 (NH), 3093 (ArH), 2929-2850 (CH2), 2230 (CN), 2083 (N3),
1631 (CO), 1583 (NH-CO), 1477 (NH-CO). 1H NMR (500 MHz,
CDCl3, d ppm): 1.75 (p, 2H, CH2), 2.02 (t, 2H, N3-CH2), 3.30 (m, 6H,
SCH2, CH2, NHCH2), 5.9 (s, NH), 7.51 (d,d, 1H, ArCH), 7.55 (s, d,
1H, ArH), 7.60 (d, 1H, ArH). 13C NMR (125 MHz, CDCl3, d ppm):
27.38 (NH2CH2CH2N3), 28.64 (NHCH2), 34.97 (SCH2), 37.45
(SCH2CH2), 49.38 (CH2N3), 111.07 (CN), 115.10 (Ar), 115.53 (CN),
116.24 (CN), 130.20 (Ar), 133.57 (Ar), 146.41 (Ar-S), 169.79 (CO).
MS (ESI) m/z [M+Na]+ 337.09. m/z calculated for C14H14N6OS [M]
+
314.37.
Synthesis of 2-(N-(3-azidopropyl)-(3-thiopropane)amide) 9,10,16,17,
23,24-(1-mercapto-4,7,10-trioxaundecane) Zn(II) phthalocyanine (6) . N-
(3-azidopropyl)-3-((3,4-dicyanophenyl)thio)propanamide 4 (50 mg,
0.16 mmol) and 4,5-bis(4,7,10-trioxaundecane-1-sulfonyl) phthalonitrile 1
(670 mg, 1.44 mmol) were dissolved in anhydrous dimethylaminoethanol
(2 mL) under argon atmosphere and stirred for 20 min. Then Zn(OAc)2
(150 mg, 0.80 mmol) was added and solution was reﬂuxed for further
1 h at 120°C, then the reaction was cooled down. The reaction mixture
was evaporated under reduce pressure. A crude green mixture of symmet-
ric derivative 5 and desired asymmetric derivative 6 was puriﬁed by col-
umn chromatography over bio-beads using CH2Cl2 as eluent, then the
two derivatives were separated on preparative silica gel TLC using
CH2Cl2: CH3CH2OH (13:1) as the eluent. Yield: 28% (68 mg). (FT-IR
(cm1) 3308 (NH), 2922, 2857 (CH2), 2093 (N3), 1641 (amide CO).
1H
NMR (500 MHz, DMF-d7, d ppm): 1.28 (s, H, NH), 1.87 (t, 2H,
CH2N3), 3.25-3.29 (m, 18H, OCH3), 3.34-3.41 (m, 2H, CH2CH2N3),
3.48-3.53 (m, 6H, COCH2, SCH2, NHCH2), 3.58-3.67 (m, 12H, SCH2),
3.72-3.90 (m, 48H, OCH2), 4.16-4.19 (m, 12H, SCH2CH2O), 8.22 (br,s,
2H, ArH), 8.84-9.26 (m, 7H, ArH). 13C NMR (125 MHz, DMF-d7, d
ppm): 28.94 (CH2), 33.23 (CH2), 33.59(CH2), 33.59(CH2), 33.75(CH2),
35.11(CH2), 35.45(CH2), 36.45(CH2), 48.98(CH2N3), 58.04(OCH3),
69.50(CH2), 69.69(CH2), 70.25(CH2), 70.43(CH2), 70.51(CH2), 71.79
(SCH2), 121.41(Ar) 135.47 (Ar), 135.66 (Ar), 136.17(Ar), 137.76(Ar),
138.45(Ar), 139.17(Ar), 152.90 (Ar-S), 170.06 (CO). HRMS (MALDI-
TOF) m/z [M+H]+ calculated for C80H110N12O19S7Zn 1833.6252; found
1833.6336 (mass accuracy 4.58 ppm). UV-Vis (DMSO) kmax nm (log e)
371.5 (4.86) and 705.5 (4.93).
Synthesis of 2–(N-(3-Gd595-propyl)-(3-thiopropylamide)-9,10,16,17,
23,24-(1-mercapto-4,7,10-trioxaundecane) Zn(II) phthalocyanine (8). 2-
(N-(3-azidopropyl)-(3-thiopropyl)amide)-9,10,16,17,23,24-(1-mercapto-
4,7,10 trioxaundecane) Zn(II) phthalocyanine 6 (40 mg, 0.022 mmol),
Gd-595 (7) (45 mg, 0.077 mmol), sodium ascorbate (29 mg, 0.15 mmol)
and copper sulfate were dissolved in a water/DMF (1:1) mixture (1 mL).
The mixture was heated at 60°C for 48 h, then cooled down and loaded
into a dialysis bag with MWCO 2000, and dialyzed for 48 h against Mil-
lipore water. The absence of residual free Gd3+ ion was conﬁrmed with
the xylenol orange indicator test in an aqueous solution of the complex
8. The ﬁnal reaction mixture was lyophilized and run through a BioBe-
ads© (BioRad SX2) column using DCM as the eluent. Puriﬁcation by
column chromatography on cellulose with CH2Cl2 and then DCM/EtOH
(10:1) as solvent gave the desired product. Yield: 45% (24 mg). FT-IR
(cm1) 3268 (NH), 2870 (CH2), 1594 (Gd-595-CO), 1371 (triazole ring).
HRMS (MALDI-TOF) m/z [M+H]+ calculated for C80H110N12O19S7Zn
2430.7789; found 2430.7882 (mass accuracy 3.82 ppm). UV-Vis
(DMSO) kmax nm (log e) 390 (4.60), 705 (5.01).
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X-ray data collection and structure reﬁnement. Unit cell measure-
ments and intensity data collection were performed on an Bruker APEX
II QUAZAR three-circle diffractometer using monochromatized Mo Ka
X–radiation (k = 0.71073 A) using φ and x technique. Indexing was
performed using APEX2 (46). Data integration and reduction were car-
ried out with SAINT V8.27B (47). Absorption correction was per-
formed by multiscan method implemented in SADABS V2012/1 (48).
The structure was solved using the direct methods procedure in SHEL-
XS-97 (49) and then reﬁned by full-matrix least-squares reﬁnements on
F2 using the SHELXL-97. All non-hydrogen atoms were reﬁned aniso-
tropically using all reﬂections with I > 2r(I). C-bound H-atoms were
positioned geometrically and reﬁned using a riding mode. The N-bound
H atom was located from the difference Fourier map and restrained to
be 0.89 A from N atom using DFIX and its position was constrained
to reﬁne on its parent N atom with Uiso(H) = 1.2 Ueq(N). Crystallo-
graphic data and reﬁnement details of the data collection for 4 are
given in Table S1. The ﬁnal geometrical calculations and the molecular
drawings were carried out with Platon v1.16 (50) and Mercury CSD
3.1 program (51).
EPR measurements. The solution EPR spectrum was recorded in solu-
tion (chloroform) with a Jeol JES FA 300 X-bandspectrometer
(8.96 GHz) with about 1mW microwave power and 100 kHz magnetic
ﬁeld modulation, at room temperature.
Photophysics and photochemistry. Instrumentation. Absorption
spectra in the UV-Visible region were recorded with a Shimadzu 2001
UV spectrophotometer. Fluorescence excitation and emission spectra
were recorded on a Varian Eclipse spectroﬂuorometer using 1 cm path-
length cuvettes at room temperature. Photo-irradiations were done using
a General Electric quartz line lamp (300W). A 600 nm glass cut off ﬁlter
(Schott) and a water ﬁlter were used to ﬁlter off ultraviolet and infrared
radiations respectively. An interference ﬁlter (Intor, 700 nm with a band
width of 40 nm) was additionally placed in the light path before the sam-
ple. Light intensities were measured with a POWER MAX5100 (Mol-
electron detector incorporated) power meter.
Fluorescence quantum yield determination. Fluorescence quantum
yield (ΦF) was estimated by the comparative method (Eq. 1) (52,53)
using unsubstituted Zn(II) phthalocyanine (ZnPc) as the reference. Refer-
ence value of ΦF is 0.18 in DMSO for ZnPc (54)
UF ¼ UFðStdÞ F:AStd:n
2
FStd:A:n2Std
ð1Þ
where F and FStd are the areas under the ﬂuorescence emission curves of
the sample and the standard, respectively. A and AStd are the respective
absorbances of the sample and standard at the excitation wavelengths. n2
and n2Std are the refractive indices of solvents used for the sample and
standard, respectively. The absorbance of the solutions at the excitation
wavelength ranged between 0.1 and 0.02.
Singlet oxygen quantum yield determination. Singlet oxygen quantum
yield (ΦD) was determined in air using the relative method (55) with
ZnPc (in DMSO) or ZnPcSmix (in aqueous media) as the reference.
DPBF (1,3-diphenylisobenzofuran) and ADMA (anthracene-9,10-bis-
methylmalonate) were used as chemical quencher for singlet oxygen,
respectively in DMSO and aqueous media, using Eq. (2):
UD ¼ UStdD
R:IStdabs
RStd:Iabs
ð2Þ
where UStdD is the singlet oxygen quantum yield for the standard ZnPc
(UStdD = 0.67 in DMSO) (54) and ZnPcSmix (U
Std
D = 0.45 in aqueous
media) (56) and R and RStd are the DPBF photobleaching rates in the
presence of the respective sample and standards, respectively. Iabs U
Std
abs
and are the rates of light absorption by the sample and standards, respec-
tively. To avoid chain reactions induced by the initial photo-oxidative
product of the reaction between DPBF (or ADMA) and singlet oxygen
(56), the concentration of quenchers (DPBF or ADMA) was lowered to
~3 9 105 M. Solutions of the photosensitizer containing DPBF (or
ADMA) were prepared in the dark and irradiated in the Q-band region
using the setup described in equipment part. DPBF degradation at
417 nm and ADMA degradation at 380 nm (in water) were monitored.
The light intensity of 7.05 9 1015 photons s1 cm2 was used for ΦD
determinations.
Photodegradation quantum yield determination. Photodegradation
quantum yield (Φd) determination was carried out using the experimental
setup described in literature (57,58). Φd value was determined using
Eq. (3),
Ud ¼ ðC0  CtÞ:V:NAIabs:S:t ð3Þ
where C0 and Ct are respectively the sample concentrations before and
after irradiation, V is the reaction volume, NA the Avogadro’s constant,
S the irradiated cell area and t the irradiation time, Iabs is the overlap
integral of the radiation source light intensity and the absorption of the
sample. A light intensity of 2.20 9 1016 photons s1 cm2 was
employed for Φd determinations.
Relaxivity (r1) measurements. MRI relaxivity measurements were per-
formed on a Siemens 3T TIMTrio Scanner (Siemens Medical Solutions,
Erlangen, Germany) at 37°C. The presence of paramagnetic Gd(III) in
the complexes resulted in an enhancement of the longitudinal relaxation
rate of water protons (1/T1). Aqueous solutions of Gd(III) complexes
were prepared at various concentrations (0.05, 0.10, 0.20, 0.40, 0.80 and
1.60 mM). A 3 mL glass sample holder (d = 10 mm) was placed in the
isocenter of the magnet. Spin-echo pulse sequences with multiple spin
echoes of various repetition times were utilized to obtain pixel-by-pixel
T1 maps of each sample. T1 relaxation times were measured from large
regions of interest and results were inverted to obtain the R1(1/T1) relaxa-
tion rate in s1. MR imaging capabilities of the Gd(III) complex was
examined at 3 T with the following parameters; point resolution: 1 mm,
number of slices: 3, slice thickness: 2.3 mm, echo time (TE): 7.8 ms,
repetition time (TR): 50, 100, 200, 500, 750, 1000, 2000, 7000 ms. T1
values were calculated by ﬁtting recovery times to the following Eq. (4)
in Matlab;
f ðtÞ ¼ að1 et=T1Þ þ c ð4Þ
The inverse of the longitudinal relaxation time (R1, s
1) was plotted
against Gd(III) complex concentration (mM) and ﬁtted to a straight line
with R2 > 0.99. The slope of the ﬁtted line was taken as the relaxivity
(r1, mM
1s1).
Cell viability. Human breast adenocarcinoma cells (MCF-7) were
grown to conﬂuence at 37°C under 5% CO2 in Dulbecco’s Modiﬁed
Eagle Serum (DMEM) containing 1% penicillin/streptomycin, 10%
fetal bovine serum (FBS) and 2 mM L-glutamine. The cells were
seeded in 96-well plates at an initial density of 1 9 104 cells/well.
24 h after cell seeding, phthalocyanine complex was added to ﬁnal
concentrations of 1, 5, 10, 20 and 50 lM, respectively (n = 4). After
24 h, 48 h and 72 h incubation, viability of cells was evaluated by
using Alamar blue assay according to manufacturer’s instructions.
SpectraMax M5 microplate reader (Molecular Devices) was used for
analysis.
Confocal microscopy. MCF-7 cells were seeded in 24-well plates at
an initial cell density of 5 9 103 cells/well. After 24 h incubation period,
the cells were treated with 10 lM conjugate 8 at 37°C for 24 h in a
humidiﬁed chamber with 5% CO2. After 24 h, cells were washed three
times with phosphate-buffered saline (PBS), ﬁxed with 4% paraformalde-
hyde in PBS, covered with mounting medium and coverslip and stored at
20°C. The samples were imaged with Zeiss LSM-510 confocal micro-
scope with an oil-immersion 639 objective lens. An argon laser of
488 nm wavelength was used.
RESULTS AND DISCUSSION
Synthesis and characterizations
On a molecular design point of view, A3B substitution pattern of
the phthalocyanine appeared to be the best, one isoindole subunit
bearing the DOTA unit and the three other isoindole subunits
bearing biocompatible water-solubilizing moieties. The design of
such a conjugate and this choice of the A3B substitution pattern,
in which one phthalocyanine core is coupled to one Gd-DOTA
unit, takes into account the working concentrations in both thera-
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peutic methods, which are both compatible in the micromolecular
range (59).
Common drawbacks of phthalocyanines are the regioisomeric
mixtures and their important aggregation tendency due to pi-
stacking opportunity between two macrocycles, often enhanced
in water. Polyethylene glycol substitution was proved to be a
good substitution pattern for photosensitizing phthalocyanines
(30,31). To avoid regioisomeric mixtures detrimental to further
clinical tests, peripheral disubstitution pattern was selected,
using thiol functionalized polyethylene glycol chains (30). If
free-base phthalocyanines exhibit good ﬂuorescence, better sin-
glet oxygen generation is observed when the phthalocyanine is
coordinated to a metal or a pseudo-metal such as Zn(II), Al(III),
Ga(III), Si(IV). Zn metalation is the most common and was
selected for these works. The resulting complex designed here
is a bimetallic molecule, the Gd-DOTA for the MRI effect and
the Zn metalation of the phthalocyanine for the photodynamic
activity.
The choice of the Gd-DOTA unit coupled to a phthalocyanine
was likely to satisfy all our requirements for good imaging
results: fast water exchange, tenable rotational dynamics and lim-
ited internal motion. The efﬁciency of a contrast agent is
expressed by their relaxivity r1 and a much higher effectiveness,
achievable by tuning its physico-chemical characteristics: the res-
idence time of the water molecule(s) coordinated to the central
GdIII ion (sM) and the rotational correlation time of the whole
molecule (sR). In general, the clinically used contrast agents
have too slow water exchange rate (long sM) and too fast molec-
ular tumbling (short sR) due to their low-molecular-weight nat-
ure. As it is known that increasing the molecular size of MRI
imaging agent enhances its overall molecular relaxivity, the con-
jugation to phthalocyanine, which is a molecule of elevated
molecular weight, is expected to have a beneﬁcial effect on the
imaging properties.
On a synthetic strategy aspect, the Huisgen dipolar addition of
click chemistry is a powerful synthetic tool successfully used in
tetrapyrrolic functionalization (60) and was selected for the cou-
pling of the DOTA moiety onto the phthalocyanine. To click the
known alkynyl DOTA 7 (known as Gd-595) (59), the azido-
functionalized phthalocyanine 6 was designed.
A3B phthalocyanines are easily obtained by cyclotetrameriza-
tion reactions applied to a statistical mixture of two phthalonitr-
iles. The ﬁrst synthetic strategy envisaged was the preparation of
a monocarboxylated phthalocyanine on which introduce the
azido function (Scheme 1), but the puriﬁcation and separation of
the desired A3B from the concomitantly formed symmetric
derivative proved to be tedious. The alternative synthetic strategy
adopted was the preparation of an azidophthalonitrile, used to
obtain an A3B azidophthalocyanine, a suitable building block for
click chemistry with any molecule bearing a terminal alkyne,
and clicked hereafter onto alkynyl DOTA 7.
Azidophthalonitrile 4 is a key intermediate, prepared from
phthalonitrile 2, amidiﬁed with 3-azidopropylamine (43) using
SOCl2 in a reasonable 68% yield, and that could be crystallized
from ethanol at room temperature via slow evaporation. ORTEP
representation with atomic numbering scheme is shown in Fig.
S5. Compound 4 crystallizes in a triclinic space group (P-1). The
N-H and C=O bonds in the amide functional group are anti to
each other. The amido -NHCO- plane is nearly orthogonal to the
phthalonitrile aromatic ring (C3-C8) with the value of dihedral
angle of 76.74o. The CN bond distances of 1.142(3) A and
1.143(3) A are similar to values reported in the literature (61,62).
The azido group is not linear with the value of N6-N5-N4 angle
of 171.7(2)o.
A 9:1 ratio of starting materials has been calculated to lead to
the formation of a mixture of only two derivatives: the symmet-
ric A4 and the desired A3B phthalocyanine. This 9:1 ratio was
applied to a mixture of starting materials (phthalonitriles 1 and
4) which underwent mixed cyclotetramerization in the presence
of zinc acetate in dimethylaminoethanol, and led to the symmet-
ric phthalocyanine 5 (identiﬁed accordingly to our previous
reports (30) and the desired AAAB phthalocyanine 6, separated
by preparative thin layer chromatography. The absence of other
derivatives (except traces of A2B2 isomers), together with the
yield of 28% for the desired A3B phthalocyanine 6, is attribut-
able to the excess of phthalonitrile 1 and is excellent for this
kind of reaction (63,64). This key synthetic intermediate was
characterized by 1H and 13C NMR as well as by MALDI-TOF at
high resolution and IR spectroscopy. An intense peak at
2093 cm1 evidences the presence of the azide function (Fig.
S6).
The phthalocyanine-DOTA conjugate 8 was obtained by click
chemistry. Various conditions were tested for the click reaction.
Heating azidophthalocyanine 5 in DMF with alkynyl GdDOTA,
copper sulfate and sodium ascorbate appeared to be the most
suitable conditions, leading to the desired conjugate 8 in rather
high yield (45%). Puriﬁcation was nevertheless laborious, due to
the polarity of the conjugate inducing its sticking to silica gel
during chromatographic puriﬁcations. NMR spectroscopy is not
suitable for paramagnetic compounds, which is the case of conju-
gate 8. Its structure was ascertained by FT-IR (Fig. S9) and
MALDI spectroscopy at high resolution (Fig. 1). The experimen-
tal and theoretical isotopic patterns obtained for 8 in high-resolu-
tion conditions are ﬁtting each other, conﬁrming the structure of
desired compound 8 (Fig. 1). The EPR spectrum of conjugate 8
in chloroform was recorded in the 0-8000 G range at room tem-
perature (Fig. S11). The broad peak at about g  1.997 in the
spectrum belongs to Gd3+(S = 7/2) ions, with a peak-to-peak
linewidth, DHpp ﬃ 560 G. Since Gd3+ ion is S-state paramag-
netic ion, the orbital contribution becomes quenched, resulting in
a long relaxation time. The other peaks are background signals
from sample tube and cavity. Gd3+ ion has a 4f7 electronic con-
ﬁguration and 8S7/2 ground state. Due to zero orbital angular
momentum, it is only the trivalent lanthanide whose EPR can be
observed at room temperature. The relaxation mechanism of
Gd3+ complexes in solution is determined by zero ﬁeld splitting
(ZFS) which is caused by the exchange interactions between
unpaired electron spins, giving rise to a very broad line. In addi-
tion, inductively coupled plasma mass spectrometry (ICP-MS)
analysis was performed. This technique detects speciﬁcally met-
als and the Gd-to-Zn ratio was estimated to be ca. 1, conﬁrming
that one Gd-DOTA unit is present per Zn phthalocyanine core
(Fig. S12 and Table S2).
Photophysics and photochemistry
The photophysical and photochemical properties of the DOTA-
phthalocyanine conjugate 8 were investigated and compared
with those of the corresponding symmetrically substituted
phthalocyanine 5, used as the analogous reference without
DOTA unit (30). All the data commented below are summa-
rized in Tables 1 and 2.
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Photophysical properties. The electronic absorption spectrum of
conjugate 8 was measured in DMSO, DMF, DCM and H2O
(Fig. 2, top). One can notice that the solubility of the conju-
gate is wide ranged, from very polar solvents such as water,
to much more hydrophobic dichloromethane. The presence of
the DOTA on 8 signiﬁcantly enhanced the water-solubility
compared to reference symmetric phthalocyanine 5 (30) even
if the conjugate is still aggregated as evidenced by the blue-
shifted position and large shape of its Q band. This water-
solubility is a positive aspect for further biological experi-
ments. The fact that this was due to aggregation was con-
ﬁrmed by the addition of Triton X-100, a surfactant known to
inhibit aggregation in aqueous media (65–67). Indeed, the
sharpness of the Q band was restored upon its addition. As
further photophysical and photochemical measurements need to
be conducted on monomerized (nonaggregated) molecules, the
aggregation behavior of 8 was studied in different solvents
(Fig. 2, bottom).
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The ground-state electronic absorption spectrum of 8 in
DMSO shows characteristic absorption in the Q-band region.
The spectrum of this molecule exhibits monomeric behavior evi-
denced by a single narrow Q band which is typical of nonaggre-
gated metallated phthalocyanine complexes, and it was therefore
decided to conduct the next photophysical and photochemical
measurements in this solvent, as well as in water which is the
closest to biological medium.
Fluorescence characterization of the conjugate 8 was per-
formed. The ﬂuorescence emission spectrum of 8 is a mirror
image of the absorption spectra, which is itself similar to the
excitation spectrum (Fig. 3). Fluorescence quantum yield (ΦF) of
phthalocyanine-DOTA conjugate 8 in DMSO is given in Table 3
and has been determined using reported calculation methods
(68). This molecule does not ﬂuoresce in water, most probably
due to the aggregation described above.
Figure 1. MALDI-TOF high-resolution mass spectrum of conjugate 8.
Top: full spectrum, bottom: superposition of the theoretical (red) and
experimental (black) isotopic patterns. The observed molecular ion is
[M+H]+. Mass accuracy 3.82 ppm.
Table 1. Electronic absorption and ﬂuorescence data for conjugate 8 in
different solvents.
Solvent
Q band
kmax,
(nm)
log
e
Excitation
kEx (nm)
Emission
kEm
(nm)
Stokes
shift DStokes,
(nm)
DMSO 705 5.01 706 713 8
DMF 701 4.99 703 711 10
DCM 704 4.48 705 713 9
H2O 650 3.82 655 – –
Table 2. Photophysical and photochemical parameters of phthalocya-
nine-DOTA conjugate 8 in DMSO and H2O.
Compound Solvent ΦF Φd (910
5) ΦD
5 DMSO 0.13 (30) 22.0 (30) 0.72
8 DMSO 0.15 3.97 0.67
8 H2O – 10.8 0.10
Figure 2. Top: UV-Vis spectrum of 8 in different solvents, at a 10 lM
concentration. Bottom: Aggregation behavior of 8 in DMSO at different
concentrations: 14, 12, 10, 8, 6 and 4 lM. Inset: Plot of absorbance ver-
sus concentration. The linearity of the slope means that the Beer-Lambert
law is respected and that the compound is not aggregated.
Figure 3. Absorption (dashed line), ﬂuorescence excitation (solid line)
and emission (dotted line) spectra of 8 in DMSO. Excitation wavelength
645 nm, emission wavelength 713 nm.
Table 3. Gd(III) ionic relaxivity of conjugate 8 and Gd(III) complexes in
water at 37 °C and 128 MHz.
Compound r1 (mM
1 s1)
Conjugate 8 1.43
Gd-595 (7) 3.21 (23)
Omniscan 3.23 (79)
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As biological media are not simple water, and as we demon-
strated in previous reports that phthalocyanines monomerize in
the presence of biological membranes and other components
(69), the ﬂuorescence emission of conjugate 8 (observed in other
solvents) is likely to be an additional useful tool for tumor visu-
alization or photosensitizer distribution monitoring. As the sum
of the quantum yields cannot exceed 1, the rather low ﬂuores-
cence quantum yields can be correlated to the high singlet oxy-
gen generation yield: the excited singlet state of compound 8 is
converted into the triplet state rather than returning to its funda-
mental state by ﬂuorescence emission.
Photochemical properties. The singlet oxygen quantum yield
(ΦD) is a crucial photochemical parameter in PDT as it quantiﬁes
the ability of a photosensitizer to generate singlet oxygen. ΦD
was determined by a comparative method based on the decompo-
sition of DPBF in DMSO and ADMA in H2O. These molecules
react instantaneously with singlet oxygen via a dipolar cycloaddi-
tion, and their absorption is quenched by this reaction. Therefore,
the diminution of the absorption of DPBF in DMSO at 417 nm,
and of ADMA in water at 380 nm, is directly proportional to the
singlet oxygen generated upon irradiation (see measured spec-
trum examples in refs 9,31 and 65). The curves in DMSO and
water are presented in Fig. 4, the results are summarized in
Table 2.
Molecules which are not aggregated exhibit their maximum
singlet oxygen generation capability, as it is the case of 8 in
DMSO, in which its ΦD value is 0.67. The presence of the Gd-
DOTA moiety has no consequence on the singlet oxygen genera-
tion ability of the phthalocyanine core, which is in the same
range than the reference compound 5 (30). Minimum values to
be acknowledged as a suitable photosensitizer is above 0.5 (65),
therefore the photodynamic ability of conjugate 8 is satisfying.
ΦD value in water for conjugate 8 is lower than that of in
DMSO. This is due to the aggregation and to the quenching of
singlet oxygen by water (65). Rather than concluding than this
may prevent the use of conjugate 8 in intracellular media, one
should keep in mind that cells are complex organization is likely
to positively modify the aggregation state of the photosensitizer:
we demonstrated that in the presence of membrane, phthalocya-
nine aggregated in pure water becomes monomerized and
recover its photodynamic efﬁciency (69).
Degradation of the molecules under irradiation reﬂects their
stability. Depending on targeted applications, different values are
suitable. For photocatalysts, maximum photostability is required,
when for biological photoapplications, intermediate photostability
is preferred to limit risks of accumulative toxicity. Conjugate 8
and reference derivative 5 exhibited about similar stability with
Φd of the order of 10
5 (Table 2), with no inﬂuence of the pres-
ence of the DOTA unit. Here, the Φd value found is about the
same with zinc phthalocyanine derivatives that have been synthe-
sized before (30). Conjugate 8 is in the appropriate range for
biological applications in both DMSO and H2O.
Contrast imaging
The efﬁciency of clinically used contrast agents is expressed by
their relaxivity r1, mainly inﬂuenced by the residence time of the
water molecule(s) coordinated to the central Gd(III) ion (sM) and
the rotational correlation time of the whole molecule (sR) (70–
72). In general, the clinically used contrast agents such as Omni-
scan display slow water exchange rate (long sM) and fast
molecular tumbling (short sR) due to their low-molecular-weight
nature (73). The rotational time can be changed by increasing
the molecular weight of whole molecule by conjugation of com-
plex to a macromolecule (74–76). Meanwhile, conjugates with
higher molecular weight could show much lower relaxivity than
expected due to the local movements inducing a shortening of sR
value. These local movements can be slowed down by rigidify-
ing the spacer between the contrast agents and macromolecule
(77–79). DOTA derivatives, where the amide oxygen atom forms
a 6-membered chelate ring upon coordination of Gd(III), were
found to have a mean water residency time, which is within the
ideal range required for our purposes.
The longitudinal relaxation rate (1/T1) of conjugate 8 was
measured in water at various Gd3+ concentrations (0.05, 0.10,
0.20, 0.40, 0.80 and 1.60 mM) and is clearly concentration
dependant, as can be observed on T1-weighted MR images
(Fig. 5) where the more prominent positive contrast is achieved
for compound 8 the higher concentration.
T1 relaxivity (r1), was then determined from the slope of 1/T1
versus [Gd3+] plot (Fig. 6). r1 values of compound 8 then calcu-
lated to be 1.43 mM1 s1 (Table 3). Conjugate 8 exhibited r1
relaxivity that was compared to the values available for Gd-595
(7) and Omniscan (Table 3), and exhibited close but weaker
values, conﬁrming that the conjugate 8 retains the contrast imag-
ing property of the Gd-DOTA moiety. The weaker values may
be attributed to the amide function on the spacer arm, likely to
block the water-binding site.
Figure 4. Top: visualization of singlet oxygen generation by 8 (concen-
tration of 8 ﬁxed at 10 lM) in DMSO by quenching of DPBF. Inset:
Plot of DPBF absorbance versus time. Bottom: same measurements in
water using ADMA (concentration of 8 ﬁxed at 10 lM). Inset: Plot of
ADMA absorbance versus time.
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In vitro compatibility assessments
In order to analyze biocompatibility, cell viability in the absence
of light was investigated, to assess the relevance of the use of
conjugate 8 as a theranostic agent: a photosensitizer should actu-
ally not be toxic at the working concentrations in the absence of
light. Human breast adenocarcinoma cells (MCF-7) were treated
with conjugate 8 in ﬁnal concentrations of 1, 5, 10, 20 and
50 lM, 24 h after cell seeding (n = 4). After 24, 48 and 72 h of
incubation, viability of cells was evaluated by Alamar blue
assay. Nontreated cells were used as control group and the via-
bility of treated cells are shown relative to nontreated cells in
Fig. 7. At 24 h, conjugate 8 caused no adverse effects on viabil-
ity of cells when used between 1–20 lM of concentration. How-
ever, treatment with 50 lM of conjugate 8 decreased cell
viability to ~75%. Longer exposure times (48 and 72 h) induce
an antiproliferative effect on MCF-7 cells for 20 lM of conju-
gate 8, which remains not toxic at 1–10 lM, these concentra-
tions causing no signiﬁcant effect on cell proliferation (Fig. 7).
The cell uptake of conjugate 8 by MCF-7 cells was investi-
gated as well. Cells were seeded in 24-well plates at a density
of 5 9 103 cells/well. After a 24 h incubation period, the cells
were treated with 10 lM of conjugate 8 at 37°C for 24 h in a
humidiﬁed incubator. The samples were analyzed with Zeiss
LSM-510 confocal microscope with an oil-immersion 639
objective lens. An argon laser of 488 nm wavelength was used.
The uptake of conjugate 8 is evidenced in Fig. 8. Further sub-
cellular localization assays by colocalization with nuclear stains
are being conducted to precisely assess the distribution of conju-
gate 8.
These preliminary data demonstrate the suitability of conju-
gate 8 for further biological investigations, currently ongoing.
CONCLUSION
A novel type of theranostic combining MRI contrast imaging
and photodynamic properties has been designed and successfully
synthesized. A phthalocyanine was selected for the photody-
namic ability, in which a Gd-DOTA moiety was introduced to
add MRI contrast imaging properties. The works presented here
demonstrated the relevance of this design, as the conjugate
retains the photophysical and photochemical properties of the
phthalocyanine core: the singlet oxygen generation of the conju-
gate is in the same range as the reference without DOTA moiety.
Even though the MRI contrast imaging ability of the conjugate
is lowered compared to related commercial Gd complexes, the
data obtained are suitable for imaging purposes. In vitro assays
Figure 6. T1 relaxation rate versus the concentration of conjugate 8.
Figure 7. Exposure to 1 to 20 lM of conjugate 8 for 24 h, 48 h and
72 h did not effect viability of MCF-7 cells. However, 50 lM of reagent
signiﬁcantly decreased cell viability. Exposure to conjugate 8 reduced
cell viability in a concentration-dependent manner. Cell viability was nor-
malized to untreated cells. Data points represents mean  SEM with
n = 4. (*P = 0.05, **P = 0.01, ***P = 0.001 by one-way ANOVA/
Bonferroni multiple comparison test).
Figure 8. Cellular uptake of conjugate 8 by MCF-7 cells after incubation for 24 h at 37 °C. Confocal images of MCF-7 cells treated with 10 lM of
conjugate 8 (a,b,c).
Figure 5. T1-weighed image for conjugate 8.
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indicate an appropriate innocuousness of the conjugate at con-
centrations used for treatment. All these measurements together
conﬁrm the relevance of this new theranostic concept. Further
biological investigations are in progress.
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